Get the Daily Brief
Latest Biotech News
Decade’s Most Precise Gravitational Wave Confirms Black Hole Theories
The LIGO-Virgo-KAGRA Collaboration’s detection of GW250114 delivered the clearest gravitational wave signal to date from a binary black hole merger, providing direct confirmation of Stephen...
New Antibody Therapy Shows Broad Protection Against Influenza Strains
Scientists at the Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting conserved epitopes on influenza A virus’s matrix protein 2 ectodomain, conferring broad...
Lucid Diagnostics Plans $25 Million Public Offering Ahead of Medicare Coverage
Lucid Diagnostics announced a public offering of 25 million shares at $1 each, aiming to raise approximately $25 million to support working capital and corporate purposes. The sequencing-based...
Cancer and Immune System Interactions Reveal New Lung Tumor Insights
Multiple studies presented at recent lung cancer conferences unveil groundbreaking discoveries in tumor-immune interactions. Research from Stanford Medicine and the Icahn School of Medicine at...
Eli Lilly Opens AI Platforms to Accelerate Biotech Drug Discovery
Eli Lilly launched TuneLab, a new AI platform offering drug discovery models trained on decades of Lilly research for use by selected biotechs at no cost. The initiative aims to leverage federated...
Noa Therapeutics and Johns Hopkins Advance Novel Immune Modulating Treatment
Noa Therapeutics received a Catalyst Research Grant from the National Eczema Association to fund preclinical evaluations of its lead biased aryl hydrocarbon receptor (AhR) drug candidate at Johns...
Novartis Acquires Tourmaline Bio for $1.4 Billion to Boost Cardiovascular Pipeline
Novartis announced the acquisition of Tourmaline Bio for $1.4 billion, gaining rights to pacibekitug, an anti-IL-6 monoclonal antibody targeting atherosclerotic cardiovascular disease (ASCVD)....
FDA Approval of J&J’s Drug-Device Combo Inlexzo Offers New Bladder Cancer Option
Johnson & Johnson received FDA approval for Inlexzo (formerly TAR-200), a drug-device system releasing gemcitabine into the bladder to treat Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle...
Harvard’s AI Model PDGrapher Identifies Combinatorial Treatments to Reverse Disease States
Researchers at Harvard Medical School developed PDGrapher, an AI model that predicts gene targets capable of reverting diseased cells to healthy states by analyzing multiple disease drivers...
Breakthroughs in Cancer Therapies: Antibody–Bottlebrush Prodrugs and Immunotherapy Advances
MIT chemists introduced antibody–bottlebrush prodrugs that enable higher drug loads and payload diversity compared to traditional antibody-drug conjugates (ADCs), showing favorable preclinical...
AI Accelerates Drug Discovery: Eli Lilly Opens TuneLab Platform to Biotechs
Eli Lilly launched TuneLab, an AI platform granting biotech companies access to predictive models trained on Lilly’s extensive drug discovery data. This federated learning system protects...
Massive Gene and Protein Discoveries: Atlas Blue Butterfly Genome and Neuronal Lipid Metabolism Links
Researchers sequenced the genome of Polyommatus atlantica, the Atlas blue butterfly, identifying it as having the highest chromosome count among multicellular organisms due to chromosome...
New Diagnostic and Monitoring Advances in Lung and Prostate Cancer
University College London and collaborators demonstrated a faster, cost-effective MRI scan for prostate cancer diagnosis matching current standards. The National Cancer Center of China revealed...
Groundbreaking Long-Term CHO Cell Stability Prediction Model Developed by MIT
MIT scientists created the first publicly available artificial intelligence model predicting long-term stability of Chinese Hamster Ovary (CHO) cell lines over 72 passages, meeting FDA stability...
Emerging Trends in Immunotherapy and Targeted Lung Cancer Therapies
New clinical data highlight immunotherapy advances including Ideaya and Hengrui’s DLL3-targeting ADC IDE-849 showing promise in small-cell lung cancer. BioNTech’s bispecific pumitamig demonstrated...
Digital Innovations and New Models in Clinical Trials and Biotech Partnerships
City of Hope launched a national clinical trials model to accelerate access to emerging cancer therapies. Belgian bioinformatics firm Aspect Analytics raised €10 million to enhance spatial biology...
Novartis Expands Cardiovascular Pipeline: $1.4B Tourmaline Acquisition
Novartis has acquired Tourmaline Bio for $1.4 billion, gaining full rights to pacibekitug, an anti-IL-6 monoclonal antibody targeting atherosclerotic cardiovascular disease (ASCVD). Licensed...
Immunotherapy Breakthroughs in Lung and Small Cell Cancers
New clinical data highlight advancements in immunotherapy for lung cancers. BioNTech and Bristol Myers Squibb reported promising Phase 2 results combining PD-L1xVEGF dual-action drug pumitamig...
AI Platforms Drive Drug Discovery and Diagnostics Innovation
Eli Lilly launched TuneLab, an AI platform granting early-stage biotechs access to its sophisticated drug discovery models in exchange for data contributions. This initiative, part of Lilly’s...
Rapport Therapeutics’ Seizure Drug RAP-219 Surpasses Expectations
Rapport Therapeutics reported robust Phase IIa data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator targeting drug-resistant focal onset seizures. The open-label study showed a...